Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT
A Phase II Study of Treosulfan/Fludarabine/Low Dose Total Body Irradiation as a Preparative Regimen for Children With AML/MDS Undergoing Allogeneic Hematopoietic Cell Transplantation
Sponsor: Center for International Blood and Marrow Transplant Research
A PHASE2 clinical study on Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS), this trial is completed. The trial is conducted by Center for International Blood and Marrow Transplant Research and has accumulated 7 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Sep 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Center for International Blood and Marrow Transplant Research
- National Marrow Donor Program
- Pediatric Blood and Marrow Transplant Consortium
- Resource for Clinical Investigation in Blood and Marrow Transplantation (RCI BMT)
- St. Baldrick's Foundation
- medac GmbH
For direct contact, visit the study record on ClinicalTrials.gov .